Rebeca Ortega
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rebeca Ortega has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Bo Liu
Department of Diabetes, School of Cardiovascular and Metabolic Medicine & Sciences, Faculty of Life Sciences & Medicine King's College London London UK
2 shared publications - Shanta Jean Persaud
Department of Diabetes, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, Guy's Campus, London SE1 1UL, UK.
2 shared publications Haruhiko Omori
1 shared publication- José Tomás Real
Institute of Health Research INCLIVA, Av. Menéndez Pelayo 4, 46010 Valencia, Spain
1 shared publication - Laura Piqueras
Institute of Health Research-INCLIVA, 46010 Valencia, Spain
1 shared publication - Luisa Hueso
Institute of Health Research-INCLIVA, Valencia, Spain
1 shared publication
Latest Publications
- Open Access
- 11 February 2026
- Published by Elsevier in SSRN Electronic Journal
Effects of a curcumin-based nanoformulation on mouse islet microRNA-33 expression and islet function
Curcumin has been suggested to influence glucose homeostasis, but poor solubility and bioavailability limit understanding of its effects on β-cell function. Curcumin has also been reported to downregulate microRNA-33 (miR-33), a non-coding RNA involved in glucose homeostasis and insulin secretion. This study investigated the effects of a curcumin-based nanoformulation (Nano-CUR), designed to improve curcumin bioavailability, on miR-33 expression and islet function. Nano-CUR and a blank nanoformulation (Nano-BLK) were prepared using a modified thin-film hydration method. Mouse islets were incubated with vehicle-supplemented medium, unformulated curcumin (CUR), Nano-BLK or Nano-CUR for 24 hours. Cell viability was assessed by Trypan blue staining; insulin secretion and content were analysed via static incubation and radioimmunoassay; apoptosis was evaluated by measurement of caspase 3/7 activities; ATP production was quantified using a chemiluminescent assay; and miR-33 expression was determined by qPCR. Exposure of islets to vehicle, 5 µM CUR, 5 µM Nano-BLK, or 5 µM Nano-CUR did not compromise their viability, whereas 15 µM CUR and 15 µM Nano-BLK increased Trypan blue uptake. Noteably, 5 µM Nano-CUR, but not 5 μM CUR, enhanced basal, glucose- and carbachol-induced insulin secretion and increased insulin content, without altering basal or cytokine-induced β-cell apoptosis or ATP production. Furthermore, 5 μM Nano-CUR, but not 5 μM CUR, reduced islet miR-33a-5p expression. These findings indicate that Nano-CUR enhances β-cell function, likely via a glucose metabolism-independent mechanism involving miR-33 downregulation, highlighting its potential as a strategy to improve β-cell function.
- 11 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEffects of a curcumin-based nanoformulation on mouse islet microRNA-33 expression and islet function
Curcumin has been suggested to influence glucose homeostasis, but poor solubility and bioavailability limit understanding of its effects on β-cell function. Curcumin has also been reported to downregulate microRNA-33 (miR-33), a non-coding RNA involved in glucose homeostasis and insulin secretion. This study investigated the effects of a curcumin-based nanoformulation (Nano-CUR), designed to improve curcumin bioavailability, on miR-33 expression and islet function. Nano-CUR and a blank nanoformulation (Nano-BLK) were prepared using a modified thin-film hydration method. Mouse islets were incubated with vehicle-supplemented medium, unformulated curcumin (CUR), Nano-BLK or Nano-CUR for 24 hours. Cell viability was assessed by Trypan blue staining; insulin secretion and content were analysed via static incubation and radioimmunoassay; apoptosis was evaluated by measurement of caspase 3/7 activities; ATP production was quantified using a chemiluminescent assay; and miR-33 expression was determined by qPCR. Exposure of islets to vehicle, 5 µM CUR, 5 µM Nano-BLK, or 5 µM Nano-CUR did not compromise their viability, whereas 15 µM CUR and 15 µM Nano-BLK increased Trypan blue uptake. Noteably, 5 µM Nano-CUR, but not 5 μM CUR, enhanced basal, glucose- and carbachol-induced insulin secretion and increased insulin content, without altering basal or cytokine-induced β-cell apoptosis or ATP production. Furthermore, 5 μM Nano-CUR, but not 5 μM CUR, reduced islet miR-33a-5p expression. These findings indicate that Nano-CUR enhances β-cell function, likely via a glucose metabolism-independent mechanism involving miR-33 downregulation, highlighting its potential as a strategy to improve β-cell function.
- Open Access
- 28 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 10777
Effects of miR-33 Deficiency on Metabolic and Cardiovascular Diseases: Implications for Therapeutic Intervention
MicroRNAs (miRNAs) are small noncoding RNAs that post-transcriptionally inhibit gene expression. These small molecules are involved in several biological conditions such as inflammation, cell growth and proliferation, and regulation of energy metabolism. In the context of metabolic and cardiovascular diseases, miR-33 is of particular interest as it has been implicated in the regulation of lipid and glucose metabolism. This miRNA is located in introns harboured in the genes encoding sterol regulatory element-binding protein (SREBP)-1 and SREBP-2, which are key transcription factors involved in lipid biosynthesis and cholesterol efflux. This review outlines the role of miR-33 in a range of metabolic and cardiovascular pathologies, such as dyslipidaemia, nonalcoholic fatty liver disease (NAFLD), obesity, diabetes, atherosclerosis, and abdominal aortic aneurysm (AAA), and it provides discussion about the effectiveness of miR-33 deficiency as a possible therapeutic strategy to prevent the development of these diseases.
- 28 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 10777
Open AccessEffects of miR-33 Deficiency on Metabolic and Cardiovascular Diseases: Implications for Therapeutic Intervention
MicroRNAs (miRNAs) are small noncoding RNAs that post-transcriptionally inhibit gene expression. These small molecules are involved in several biological conditions such as inflammation, cell growth and proliferation, and regulation of energy metabolism. In the context of metabolic and cardiovascular diseases, miR-33 is of particular interest as it has been implicated in the regulation of lipid and glucose metabolism. This miRNA is located in introns harboured in the genes encoding sterol regulatory element-binding protein (SREBP)-1 and SREBP-2, which are key transcription factors involved in lipid biosynthesis and cholesterol efflux. This review outlines the role of miR-33 in a range of metabolic and cardiovascular pathologies, such as dyslipidaemia, nonalcoholic fatty liver disease (NAFLD), obesity, diabetes, atherosclerosis, and abdominal aortic aneurysm (AAA), and it provides discussion about the effectiveness of miR-33 deficiency as a possible therapeutic strategy to prevent the development of these diseases.
- Open Access
- 27 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (17) , 9267
Activation of the Constitutive Androstane Receptor Inhibits Leukocyte Adhesiveness to Dysfunctional Endothelium
Leukocyte cell recruitment into the vascular subendothelium constitutes an early event in the atherogenic process. As the effect of the constitutive androstane receptor (CAR) on leukocyte recruitment and endothelial dysfunction is poorly understood, this study investigated whether the role of CAR activation can affect this response and the underlying mechanisms involved. Under physiological flow conditions, TNFα-induced endothelial adhesion of human leukocyte cells was concentration-dependently inhibited by preincubation of human umbilical arterial endothelial cells with the selective human CAR ligand CITCO. CAR agonism also prevented TNFα induced VCAM-1 expression, as well as MCP-1/CCL-2 and RANTES/CCL-5 release in endothelial cells. Suppression of CAR expression with a small interfering RNA abrogated the inhibitory effects of CITCO on these responses. Furthermore, CITCO increased interaction of CAR with Retinoid X Receptor (RXR) and reduced TNFα-induced p38-MAPK/NF-κB activation. In vivo, using intravital microscopy in the mouse cremasteric microcirculation treatment with the selective mouse CAR ligand TCPOBOP inhibited TNFα-induced leukocyte rolling flux, adhesion, and emigration and decreased VCAM-1 in endothelium. These results reveal that CAR agonists can inhibit the initial inflammatory response that precedes the atherogenic process by targeting different steps in the leukocyte recruitment cascade. Therefore, CAR agonists may constitute a new therapeutic tool in controlling cardiovascular disease-associated inflammatory processes.
- 27 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (17) , 9267
Open AccessActivation of the Constitutive Androstane Receptor Inhibits Leukocyte Adhesiveness to Dysfunctional Endothelium
Leukocyte cell recruitment into the vascular subendothelium constitutes an early event in the atherogenic process. As the effect of the constitutive androstane receptor (CAR) on leukocyte recruitment and endothelial dysfunction is poorly understood, this study investigated whether the role of CAR activation can affect this response and the underlying mechanisms involved. Under physiological flow conditions, TNFα-induced endothelial adhesion of human leukocyte cells was concentration-dependently inhibited by preincubation of human umbilical arterial endothelial cells with the selective human CAR ligand CITCO. CAR agonism also prevented TNFα induced VCAM-1 expression, as well as MCP-1/CCL-2 and RANTES/CCL-5 release in endothelial cells. Suppression of CAR expression with a small interfering RNA abrogated the inhibitory effects of CITCO on these responses. Furthermore, CITCO increased interaction of CAR with Retinoid X Receptor (RXR) and reduced TNFα-induced p38-MAPK/NF-κB activation. In vivo, using intravital microscopy in the mouse cremasteric microcirculation treatment with the selective mouse CAR ligand TCPOBOP inhibited TNFα-induced leukocyte rolling flux, adhesion, and emigration and decreased VCAM-1 in endothelium. These results reveal that CAR agonists can inhibit the initial inflammatory response that precedes the atherogenic process by targeting different steps in the leukocyte recruitment cascade. Therefore, CAR agonists may constitute a new therapeutic tool in controlling cardiovascular disease-associated inflammatory processes.